Physician profile

Aaron Wayne Sable

Physical Medicine & Rehabilitation · Warren, MI

NPI 1306856984

$1,880.24

in general payments reported to CMS, 2019-2025

23 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Scilex Pharmaceuticals INC. $457.64 2019-2022
Allergan, INC. $331.33 2019-2022
Abbvie INC. $210.40 2021-2022
Indivior INC. $134.36 2019-2022
Collegium Pharmaceutical, INC. $122.92 2019-2022
Biodelivery Sciences International, INC. $96.62 2019-2021
Sanofi-Aventis U.S. LLC $96.35 2019-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $76.11 2021-2022
Pfizer INC. $57.40 2019-2021
Amgen INC. $35.23 2019
Biohaven Pharmaceutical Holding Company Ltd. $27.95 2022
Mdd US Operations, LLC $27.18 2019
Grt US Holding, INC. $26.57 2020-2022
Ipsen Biopharmaceuticals, INC $24.19 2019
Idorsia Pharmaceuticals US INC $24.13 2022
Show all 23 companies
CompanyGeneral paymentsYearsTop products
Alkermes, INC. $23.67 2019
Lilly USA, LLC $23.37 2021
Takeda Pharmaceuticals U.S.A., INC. $21.13 2019
Hikma Pharmaceuticals USA $14.77 2022
Kowa Pharmaceuticals America, INC. $13.21 2022
Astrazeneca Pharmaceuticals Lp $12.41 2019
Horizon Therapeutics Plc $12.06 2022
Kaleo, INC. $11.24 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Aaron Wayne Sable

$1,880.24

in general payments reported 2019-2025

Years
2019-2022
Top company
Scilex Pharmaceuticals INC.

https://glasscript.com/doctor/104097/aaron-wayne-sable

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.